WHO Drug Information Vol. 24, No. 4, 2010

WHO Drug Information, Vol. 24, No. 4, 2010 Proposed INN: List 104mavoglurantummavoglurantmavoglurantmavoglurantmethyl (3aR,4S,7aR)-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]octahydro-1H-indole-1-carboxylateglutamate receptor antagonist(3aR,4S,7aR)-4-hydroxy-4-[2-(3-méthylphényl)éthynyl]octahydro-1H-indole-1-carboxylate de méthyleantagoniste des récepteurs au glutamate(3aR,4S,7aR)-4-hidroxi-4-[2-(3-metilfenil)etinil]octahidro-1H-indol-1-carboxilato de metilantagonista del receptor de glutamatoC 19 H 23 NO 3 543906-09-8HHOH 3 CHONOCH 3mericitabinummericitabineméricitabinemericitabina(2'R)-2'-deoxy-2'-fluoro-2'-methyl-2',3'-bis-O-(2-methylpropanoyl)cytidineantiviral3',5'-bis(2-méthylpropanoate) de (2'R)-2'-déoxy-2'-fluoro-2'-méthylcytidineantiviral(2'R)-2'-desoxi-2'-fluoro-2'-metil-2',3'-bis-O-(2-metilpropanoil)citidinaantiviralC 18 H 26 FN 3 O 6 940908-79-2CH 3NH 2H 3 COONOOH 3 CNCH 3H 3 COFOmogamulizumabum #mogamulizumabimmunoglobulin G1-kappa, anti-[Homo sapiens CCR4 (chemokine(C-C motif) receptor 4, CC chemokine receptor 4, CCR-4, CKR4, k5-5, CD194)], humanized monoclonal antibody;gamma1 heavy chain (1-449) [humanized VH (Homo sapiensIGHV3-21*01 (83.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -Homosapiens IGHG1*01 (120-449)], (222-219')-disulfide with kappa lightchain (1'-219') [humanized V-KAPPA (Homo sapiens IGKV2-29*02(81.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01(113'-219')]; (228-228":231-231")-bisdisulfide dimerimmunomodulator381